{"filings":[{"id":1177283,"accession_number":"0001193125-26-276718","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2026-06-22T12:00:17+00:00","items":["5.02","5.07"],"status":"ready","headline":"Revolution Medicines President R&D Steve Kelsey to retire Jan 2027; becomes senior advisor from July 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Kelsey, M.D., president R&D, to retire effective Jan 4, 2027; will serve as senior advisor to CEO from July 1, 2026.","Company intends to appoint Dr. Kelsey to board of directors upon retirement, subject to board approval.","Annual meeting results: Class III directors Alexis Borisy and Mark Goldsmith elected; PwC ratified as auditor; say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94194,"accession_number":"0001193125-26-208918","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RevMed Q1 net loss $453.8M, daraxonrasib shows OS 13.2 mo in pancreatic cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Daraxonrasib Phase 3 RASolute 302: median OS 13.2 mo vs 6.7 mo chemo (HR 0.40); NDA submission planned.","Q1 2026 net loss $453.8M vs $213.4M YoY; R&D $344M, G&A $101.3M, including $44.6M incremental SBC.","Cash $1.9B at Mar 31, 2026; April 2026 financings raised $2.225B gross from stock and convertible notes.","FY 2026 GAAP operating expense guidance raised to $1.7-1.8B due to ~$80M increase in non-cash SBC.","Appointed Neil MacGregor JPAC GM, Tetsuo Endo Japan GM, Martin Voelkl Germany GM; EAP for daraxonrasib begun."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94193,"accession_number":"0001193125-26-161800","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Revolution Medicines issues $500M 0.50% convertible notes due 2033","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M 0.50% Convertible Senior Notes due 2033 under indenture with U.S. Bank Trust as trustee.","Initial conversion price ~$198.80/share (5.0302 shares per $1,000 principal).","Notes are senior unsecured, redeemable after May 2030 if stock >130% conversion price for 20 of 30 trading days.","Holders may convert before Feb 2033 only upon specified events; after that anytime until maturity.","Fundamental change triggers repurchase right at 100% principal plus accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94192,"accession_number":"0001193125-26-159289","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revolution Medicines raises ~$2.15B via equity and convertible note offerings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity offering: 10,563,381 shares at $142/sh + full over-allotment of 1,584,506 shares; net proceeds ~$1.65B.","Convertible note offering: $500M aggregate principal of 0.50% Convertible Senior Notes due 2033.","Equity closed April 16; note offering expected to close April 17; underwriters J.P. Morgan, TD Securities, Guggenheim."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94191,"accession_number":"0001193125-26-152039","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.","Daraxonrasib generally well tolerated with manageable safety profile; no new safety signals.","Trial results considered final from first interim analysis; company to submit to FDA and other global regulators.","Data to support future NDA via a Commissioner’s National Priority Voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106387,"accession_number":"0001193125-26-071517","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.","Cash $2.0B; 2026 GAAP op expenses guided $1.6-$1.7B with $180-$200M stock comp.","Phase 3 RASolute 302 (daraxonrasib in 2L PDAC) readout expected H1 2026; enrollment complete.","Initiated RASolute 305 (zoldonrasib in 1L PDAC); zoldonrasib FDA Breakthrough Therapy in NSCLC.","New RAS(ON) inhibitor RMC-5127 entered clinic; new class RM-055 Phase 1 planned Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122735,"accession_number":"0001193125-25-266836","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).","Cash, equivalents & securities $1.93B; full-year GAAP net loss guidance reaffirmed at $1.03B-$1.09B.","RASolute 302 (PDAC) enrollment winding down; data readout on track for 2026.","RASolute 304 (adjuvant PDAC) initiated; RASolute 303 (1L metastatic PDAC) expected to start this year.","New CDO Alan Sandler, U.S. GM Alicia Gardner, Europe GM Gerwin Winter appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122734,"accession_number":"0001193125-25-241736","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Revolution Medicines receives FDA national priority voucher for daraxonrasib","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted a non-transferrable voucher under the Commissioner's National Priority Voucher pilot program.","Voucher is for daraxonrasib, the company's RAS(ON) multi-selective inhibitor.","Announcement made on October 16, 2025; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139427,"accession_number":"0001193125-25-200078","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Daraxonrasib shows 35% ORR in 2L PDAC, 55% in 1L combo; Phase 3 planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2L PDAC: ORR 29-35% (RAS G12X and broader mutant), DCR 92-95%, median PFS 8.1-8.5 mo, median OS 13.1-15.6 mo.","1L monotherapy (300 mg): ORR 47%, DCR 89% among 38 evaluable patients as of July 28, 2025 cutoff.","1L combo daraxonrasib 200 mg + gemcitabine/nab-paclitaxel: ORR 55%, DCR 90% in 31 evaluable patients.","Grade ≥3 TRAEs: 34% monotherapy (2L), 35% (1L), 58% combo; most common rash, GI; 0% discontinuation in 2L.","Company plans to initiate RASolute 303, a global Phase 3 trial in 1L PDAC comparing daraxonrasib ± GnP vs GnP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139426,"accession_number":"0000950170-25-103983","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q2 net loss $247.8M; advances Phase 3 RAS trials; $2B Royalty Pharma deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $247.8M vs $133.2M YoY; R&D expenses rose to $224.1M; FY2025 net loss guidance $1.03B-$1.09B.","FDA Breakthrough Therapy Designation for daraxonrasib (KRAS G12C PDAC) and elironrasib (KRAS G12C NSCLC).","Entered $2B flexible funding agreement with Royalty Pharma; first $250M tranche received; cash $2.1B.","RASolute 302 Phase 3 trial for PDAC enrollment to complete this year; data readout expected 2026.","Plans to initiate registrational trials for first-line PDAC and adjuvant PDAC in 2025; Phase 3 for first-line NSCLC in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157005,"accession_number":"0001193125-25-151254","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Revolution Medicines stockholders elect four Class II directors, ratify PwC, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors elected: Frank Clyburn, Sandra Horning, Sushil Patel, Thilo Schroeder; each received >119M votes for.","Ratified PricewaterhouseCoopers as independent auditor for FY2025 with 157.9M votes for, 215K against.","Advisory say-on-pay approved with 145.3M votes for, 2.6M against, 10.2M broker non-votes.","Record date April 28, 2025; 186.3M shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157004,"accession_number":"0001193125-25-145242","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Revolution Medicines secures up to $2B financing from Royalty Pharma, withdraws cash runway guidance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $250M upfront from Royalty Pharma; up to $1.25B total synthetic royalty on daraxonrasib sales.","Loan facility of up to $750M senior secured term loan (SOFR+5.75%, 3.50% floor), interest-only, matures by 2032.","Additional tranches tied to daraxonrasib approval milestones; company retains global commercialization control.","Withdraws prior cash runway end date and 2025 GAAP net loss guidance; expects updated guidance in Q2 2025 earnings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157003,"accession_number":"0001193125-25-142735","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Revolution Medicines director Barbara Weber resigns ahead of 2025 annual meeting due to Tango collaboration activation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barbara Weber, M.D., resigned from Revolution Medicines board effective immediately prior to June 26, 2025 annual meeting.","Resignation triggered by activation of clinical study under collaboration with Tango Therapeutics, not due to any disagreement.","Dr. Weber also stepped down from Nominating and Corporate Governance Committee and R&D Committee.","The company has not yet named a replacement for the board vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157002,"accession_number":"0000950170-25-065618","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q1 net loss $213.4M; highlights encouraging RAS inhibitor data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $213.4M (vs $116.0M YoY); R&D $205.7M, G&A $35.0M; cash $2.1B.","FY 2025 GAAP net loss guidance reaffirmed $840M-$900M; cash runway into H2 2027.","Daraxonrasib Phase 3 PDAC trial enrollment to substantially complete in 2025; data in 2026.","Zoldonrasib G12D NSCLC ORR 61%; elironrasib G12C NSCLC ORR 56%, median PFS 9.9 mo.","Anthony Mancini named chief global commercialization officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175370,"accession_number":"0000950170-25-027707","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q4 2024 net loss $194.6M, cash $2.3B; Phase 3 PDAC enrollment target 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $194.6M vs $161.5M YoY; full year net loss $600.1M vs $436.4M.","Cash and securities $2.3B at Dec 31, 2024, up from $1.9B; $823M net raised in Dec 2024 public offering.","2025 GAAP net loss guidance $840M-$900M; cash runway expected into H2 2027.","Expects to complete enrollment in Phase 3 RASolute 302 (PDAC) in 2025 for data readout in 2026; Phase 3 RASolve 301 (NSCLC) now activating sites.","Plans to initiate two additional registrational trials for daraxonrasib in earlier-line PDAC in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192315,"accession_number":"0001193125-24-271540","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revolution Medicines raises ~$823M in underwritten public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16,576,088 common shares and pre-funded warrants for 2,173,917 shares closed Dec 5, 2024.","Public price $46.00 per share / $45.9999 per pre-funded warrant; underwriters purchased at $43.93/$43.9299.","Net proceeds ~$823M after discounts and expenses; underwriters' option exercised in full.","45-day lock-up on share sales by directors, officers and the company, subject to exceptions.","Underwriting led by J.P. Morgan, TD Securities, Goldman Sachs & Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192314,"accession_number":"0001193125-24-268404","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"RMC-6236 shows 38% ORR in NSCLC, 27-36% in PDAC; median PFS 9.8 mo and 8.5-8.8 mo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NSCLC efficacy: ORR 38% (15/40), median PFS 9.8 mo, median OS 17.7 mo in RAS G12X pts (cutoff Sept 30, 2024).","PDAC 2L: ORR 36% (G12X) and 27% (broader RAS); median PFS 8.8 and 8.5 mo; 6-mo OS 100% and 97% (cutoff Jul 23, 2024).","PDAC safety at 300 mg: 34% Grade ≥3 TRAEs, no Grade 5; median duration 5.2 mo, mean dose intensity 89%.","NSCLC safety: Grade ≥3 TRAEs 27% overall, 41% at 300 mg; one Grade 4 pneumonitis at 300 mg; median duration 5.5 mo (120-220 mg).","Combination RMC-6236+RMC-6291 in KRAS G12Ci-experienced CRC: ORR 25% (3/12), DCR 92%; plans for Phase 3 NSCLC trial vs docetaxel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192313,"accession_number":"0000950170-24-122266","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RevMed Q3 net loss $156M; Phase 3 PDAC trial started, RMC-9805 initial data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $156.3M for Q3 2024 vs. $108.4M in Q3 2023; R&D expenses rose to $151.8M.","Cash, equivalents and securities were $1.55B as of Sept 30, 2024; funding projected into 2027.","Phase 3 RASolute 302 trial of RMC-6236 in metastatic PDAC dosed first patient; data event-driven.","Initial RMC-9805 (KRAS G12D inhibitor) data show encouraging safety and antitumor activity; 1200 mg once daily candidate Phase 2 dose.","FY 2024 GAAP net loss guidance reiterated at $560M-600M; NSCLC and combination data due in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192312,"accession_number":"0001193125-24-243431","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Revolution Medicines reports RMC-9805 clinical data: 30% ORR in 2L+ PDAC at 1,200 mg/day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RMC-9805 monotherapy showed no Grade 4/5 TRAEs, no discontinuations; 3% dose reduction rate overall (179 patients).","For 2L+ PDAC patients (n=40) at 1,200 mg/day, ORR 30% (confirmed + pending), DCR 80%.","Most common any-grade TRAEs at 1,200 mg/day: nausea (27%), diarrhea (20%), vomiting (15%), rash (10%).","Median treatment duration 2.8 months across all doses; data cutoff September 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192311,"accession_number":"0001193125-24-241397","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"RMC-6236 shows 8.5-month median PFS in 2L metastatic PDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS of 8.5 months (95% CI: 5.3-11.7) in 2L PDAC with KRAS G12X; 4.4 months in 3L+.","Median OS of 14.5 months in 2L PDAC; 6-month OS rate 89% (KRAS G12X) and 91% (broader RAS mutant).","ORR 29% (2L) and 22% (3L+); disease control rate 91% (2L) and 89% (3L+).","Safety: 98% any grade TRAEs, 29% Grade≥3; no discontinuations; mean dose intensity 92%.","Data cutoff July 23, 2024; 127 PDAC patients across 160-300 mg daily doses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208795,"accession_number":"0000950170-24-092735","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Revolution Medicines Q2 net loss $133M; advances RMC-6236 toward Phase 3 in PDAC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $133.2M vs $98.3M YoY; revenue zero due to Sanofi collaboration termination.","Cash $1.59B; projects funding into 2027; FY 2024 GAAP net loss guidance $560-600M.","RMC-6236 in PDAC: median PFS 8.1 months (KRAS G12X); Phase 3 RASolute 302 planned for 2L this year.","Board appoints Frank Clyburn, former Merck Keytruda leader; new senior hires in medical affairs.","R&D expenses $134.9M vs $98.0M; G&A $21.7M vs $14.6M, driven by clinical and commercial prep."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208794,"accession_number":"0001193125-24-178836","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Revolution Medicines guides 2024 net loss $560-600M; RMC-6236 shows 8.1-month PFS in 2L PDAC, Phase 3 planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for FY2024 expected $560-600M, including $70-80M non-cash stock-based comp.","Cash runway into 2027; current cash, equivalents, and marketable securities sufficient.","RMC-6236 in 2L metastatic PDAC: median PFS 8.1 months (KRAS G12X); ORR 27% (20+ weeks treatment).","Safety: 96% any-grade TRAEs, 22% Grade ≥3; 0% discontinuation; dose intensity 94%.","Plans to initiate randomized Phase 3 RASolute 302 in 2H 2024 vs investigator's choice chemo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226552,"accession_number":"0001193125-24-166939","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Revolution Medicines annual meeting votes approve all three proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors: Elizabeth McKee Anderson (107.1M for), Flavia Borellini (107.3M for), Lorence Kim (97.4M for); broker non-votes 17.7M.","Ratified PricewaterhouseCoopers as independent auditor for FY2024: 148.1M for, 9.9K against, 67.4K abstentions.","Approved non-binding advisory vote on executive compensation: 128.9M for, 1.6M against, 27K abstentions; broker non-votes 17.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226551,"accession_number":"0000950170-24-055606","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q1 net loss $116M; cash $1.70B; plans pivotal RMC-6236 trials in H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $116.0M for Q1 2024, compared to $68.1M in Q1 2023.","Revenue $0 (ended Sanofi collaboration); R&D expenses $118.0M (up from $68.9M).","Cash $1.70B as of March 31, 2024; projected cash runway into 2027.","Plans to initiate two pivotal monotherapy trials of RMC-6236 in 2L PDAC and 2L NSCLC in H2 2024.","Reiterates FY2024 GAAP net loss guidance between $480M and $520M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245552,"accession_number":"0000950170-24-020125","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines reports Q4 net loss $161.5M; cash $1.85B; pipeline on track for pivotal trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $161.5M vs $56.5M YoY; full year net loss $436.4M vs $248.7M YoY.","Revenue fell to $0.7M (Q4) and $11.6M (FY) due to Sanofi collaboration termination in 2023.","Cash, equivalents and securities $1.85B as of Dec 31, 2023, up from $644.9M a year ago (EQRx acquisition and equity offering).","Plans to start pivotal Phase 3 trials for RMC-6236 in 2L NSCLC and 2L PDAC in H2 2024.","2024 GAAP net loss guidance $480M-$520M; cash runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":11580000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245551,"accession_number":"0001193125-24-005061","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Revolution Medicines posts corporate presentation; no specific financial updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated January 9, 2024, titled 'On Target to Outsmart Cancer' posted on IR website.","Presentation outlines oncology pipeline strategy; no financial results, guidance, or material developments provided.","No new clinical data or major corporate events were disclosed in the filing or accompanying exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263013,"accession_number":"0001193125-23-302252","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K/A","filed_at":"2023-12-26T23:59:59+00:00","items":["9.01","2.01"],"status":"ready","headline":"Revolution Medicines issues 54.8M shares for EQRx acquisition; pro forma shows $513M net loss","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Nov 8, 2023; issued 54.8M shares valued at ~$1.086B based on $20.02 RVMD price.","EQRx contributed $315.7M cash and $896.6M marketable securities; accounted as capital-raising with asset acquisition.","Pro forma combined cash & securities = $2.01B; net loss for 9M 2023: $513M; FY2022: $443M.","One-time transaction costs of $14M and severance of $11.8M recorded as equity reductions and accruals.","Pro forma EPS $(3.24) for 9M 2023 and $(3.27) for FY2022, on 158.5M and 135.4M weighted shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263018,"accession_number":"0001193125-23-274137","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.01","5.02","5.07","7.01","9.01"],"status":"ready","headline":"Revolution Medicines completes acquisition of EQRx; exchange ratio 0.1112","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Nov 9, 2023; EQRx stockholders received 0.1112 shares of RVMD common per EQRx share.","EQRx common stock and warrants delisted from Nasdaq; EQRx ceases as separate public company.","Sandra J. Horning appointed to RVMD board as EQRx designee, effective upon closing.","Share issuance proposal approved by ~90% of votes cast at special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263017,"accession_number":"0000950170-23-059374","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q3 net loss $108.4M; updates on RMC-6236, RMC-6291; EQRx close imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 net loss $108.4M vs $73.3M; revenue $0 vs $3.4M; R&D spend $107.7M (+55%).","Cash $813.2M; updated FY2023 net loss guidance $385-$415M; cash runway into 2025.","Promising clinical data for RMC-6236 (RAS MULTI) and RMC-6291 (RAS G12C); Phase 3 plans for NSCLC and PDAC in 2024.","EQRx acquisition expected to close Nov 2023; all-stock deal, ~55M shares issued, adds ~$1.1B net cash (~$20/share issued)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":10838000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263016,"accession_number":"0001193125-23-267696","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Revolution Medicines sets final merger exchange ratio at 0.1112; ISS/Glass Lewis back deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Final exchange ratio: 0.1112 RVMD shares per EQRx share, up from illustrative 0.0734.","ISS and Glass Lewis recommend RVMD stockholders vote FOR the share issuance.","Merger expected to add ~$1.1B net cash (~$20 per share issued); close targeted Nov 2023.","RVMD to issue ~55M shares (excl. warrants/earn-outs) for the acquisition.","RVMD special meeting of stockholders scheduled for November 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263015,"accession_number":"0001193125-23-260299","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Revolution Medicines reports Phase 1/1b data for RMC-6236 in NSCLC and PDAC; plans Phase 3 in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RMC-6236 showed ORR 38% (DCR 85%) in evaluable NSCLC (n=40) and ORR 20% (DCR 87%) in PDAC (n=46) as of Oct 12, 2023.","Safety at ≥80 mg daily: mostly Grade 1-2 rash/GI events; one Grade 4 perforation led to discontinuation; no fatal TRAEs.","Company plans global randomized Phase 3 trial of RMC-6236 vs docetaxel in RAS-mutated NSCLC, aiming to start in 2024.","Potential Phase 3 vs physician's choice in PDAC and combo pivotal trials also planned, pending further data and regulatory feedback.","RMC-4630 combo with sotorasib showed additive toxicity without sufficient benefit; no further development for that combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263014,"accession_number":"0001193125-23-255878","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Revolution Medicines reports positive clinical data for RMC-6236 and RMC-6291; selects RMC-5127","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RMC-6236 shows acceptable safety in 131 patients; common TRAEs include rash (70%) and GI toxicities, mostly Grade 1-2.","RMC-6236 demonstrates dose-dependent exposure and ctDNA reductions across NSCLC, PDAC, and multiple KRAS mutations.","RMC-6291 achieves 50% ORR in NSCLC (prior G12Ci) and 43% in G12Ci-naïve; 40% ORR in CRC with 80% DCR.","RMC-6291 safety includes 25% QTc prolongation (11% Grade 3) but no cardiac sequelae or hepatotoxicity signal.","RMC-5127, an oral covalent tri-complex inhibitor of KRAS G12V (ON), selected as a development candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280211,"accession_number":"0001193125-23-228515","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Board member Eric Schmidt resigns; Lorence Kim named Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric T. Schmidt resigned from Board and Audit Committee, effective Sept 5, 2023, to become an investment analyst.","Resignation was not due to any disagreement with Revolution Medicines.","Lorence Kim appointed Chair of Audit Committee; Alexis Borisy appointed to Audit Committee to fill vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280210,"accession_number":"0000950170-23-039773","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q2 net loss $98.3M; clinical updates for RMC-6236 and RMC-6291","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $98.3M vs $61.2M YoY; revenue from Sanofi collaboration $3.8M, down from $9.1M.","Cash, equivalents and securities $909.5M at June 30, 2023, up from $644.9M at Dec 31, 2022.","FY 2023 GAAP net loss guidance $360M–$400M; cash expected to fund operations into 2025.","Planning pivotal single-agent trials for RMC-6236; combination trial with RMC-6291 starting in early 2024.","Clinical data for RMC-6236 and RMC-6291 to be presented at ESMO and Triple Meeting in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":10838000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280209,"accession_number":"0001193125-23-199907","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Revolution Medicines to acquire EQRx in stock deal valued at ~$1.07B; pipeline updates and FY2023 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration: $200M fixed (7.69M shares) plus $870M based on pre-meeting VWAP with 6% discount; expected close Nov 2023.","Voting agreements secured with >40% of EQRx shares and ~8% of RVMD shares to support the transaction.","Company confirms FY2023 GAAP net loss guidance of $360M-$400M, inclusive of $40M-$50M stock-based compensation.","Pipeline updates: RMC-6236 clinical data in NSCLC/pancreatic cancer expected Oct 2023; planning pivotal trials for 2024.","Post-merger, company will not advance EQRx pipeline; EQRx programs to be wound down and IP returned to partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298747,"accession_number":"0001193125-23-164446","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Revolution Medicines 2023 annual meeting results: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alexis Borisy re-elected to Class III with 41.5M votes for, 48.0M withheld; Mark Goldsmith and Barbara Weber elected with margins >70M.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 94.9M for, 6,594 against.","Non-binding advisory vote on named executive officer compensation passed with 88.7M for, 0.8M against, 5.3M broker non-votes.","Only three proposals were voted on; no other items presented at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298746,"accession_number":"0000950170-23-018785","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q1 net loss $68.1M, cash $909.8M; guides FY net loss $360-400M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $68.1M for Q1 2023 vs $57.6M loss in Q1 2022; R&D expenses $68.9M (up 22% YoY).","Cash $909.8M as of March 31, 2023, up from $644.9M in Dec 2022, boosted by $345M public offering in March.","Updated FY 2023 GAAP net loss guidance to $360-$400M; cash runway projected into 2025.","Appointed Wei Lin, M.D., as CMO; also hired senior VPs for commercial, regulatory, CMC.","Clinical progress: RMC-6236 data update mid-2023; RMC-6291 preliminary report H2 2023; RMC-9805 first patient dosing mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":7014000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318940,"accession_number":"0001193125-23-062952","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revolution Medicines closes public offering of 15.7M shares for $323.6M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 15,681,818 shares of common stock at $22.00 per share to the public.","Underwriters purchased at $20.68 per share; net proceeds of approx. $323.6M.","Full exercise of underwriters' option; 30-day option period for additional 2M shares.","Company and insiders subject to 60-day lock-up from prospectus date.","Lead underwriters: J.P. Morgan, Cowen, SVB Securities, Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318939,"accession_number":"0000950170-23-004638","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines reports FY2022 net loss $248.7M; cash $644.9M; provides clinical updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $248.7M for FY2022 vs $187.1M in 2021; Q4 net loss $56.5M.","Cash, equivalents and securities $644.9M as of Dec 31, 2022; expects to fund operations through 2024.","Revenue $35.4M in FY2022 includes $7.6M non-cash adjustment from Sanofi collaboration termination.","RMC-6236 shows early antitumor activity: 12 evaluable patients all stable or better, 10 with tumor reductions, 2 partial responses.","Sanofi terminates SHP2 collaboration effective June 2023; Revolution regains global rights to RMC-4630."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":35380000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318938,"accession_number":"0000950170-23-000597","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Revolution Medicines reaffirms FY2022 net loss guidance of $245M–$265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss expected to be between $245M and $265M for the year ended December 31, 2022.","Includes estimated non-cash stock-based compensation of approximately $30M to $35M.","Company also posted a corporate presentation on January 10, 2023, covering its R&D pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":35380000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337167,"accession_number":"0001193125-22-300162","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Revolution Medicines receives termination notice from Genzyme (Sanofi) for collaboration deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Genzyme terminated the June 2018 collaboration agreement for convenience; effective June 4, 2023.","Notice received December 6, 2022; agreement had been disclosed in prior SEC filings.","No financial impact or termination fees disclosed in the filing.","Company may lose expected future collaboration revenue from Sanofi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337166,"accession_number":"0001193125-22-279068","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines reports Q3 net loss $73.3M; cash $655M; clinical trials progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $73.3M for Q3 2022, up from $52.9M in Q3 2021; revenue $3.4M from Sanofi collaboration.","Cash, equivalents, and marketable securities $655M as of Sep 30, 2022, boosted by July 2022 equity offering of $264.5M gross.","Phase 1/1b trials ongoing for RMC-6236 (RAS MULTI) and RMC-6291 (KRAS G12C); first data expected in 2023.","RMC-9805 (KRAS G12D) first patient dosing expected mid-2023.","Full-year 2022 GAAP net loss guidance reiterated at $260M-$280M; cash runway through 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":20050000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354537,"accession_number":"0001193125-22-236516","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Revolution Medicines promotes Jack Anders to CFO effective Sept 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Anders, age 45, appointed CFO effective immediately; previously SVP Finance and Principal Financial and Accounting Officer.","Anders joined Revolution Medicines in August 2018; prior roles at Depomed (VP Finance), Elan Pharmaceuticals, Yahoo!, and Novellus Systems.","He began his career at PricewaterhouseCoopers and holds a B.A. in Economics from UCLA; formerly a CPA.","Anders will continue as Principal Financial and Accounting Officer; no departure of prior CFO announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354536,"accession_number":"0001193125-22-216147","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q2 net loss $61.2M; advances first two RAS(ON) inhibitors into clinic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.2M in Q2 2022 vs $44.3M in Q2 2021; revenue from Sanofi collab $9.1M.","Cash, equivalents and securities $461.4M at June 30, 2022; July public offering raised $264.5M gross.","Updated FY 2022 GAAP net loss guidance to $260-280M; stock-based comp $30-35M.","First patient dosed in Phase 1/1b trial of RAS(ON) inhibitor RMC-6236; site activation for RMC-6291 underway.","Appointed Lorence Kim (ex-Moderna, Goldman Sachs) and Sushil Patel (ex-Genentech) to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":16694000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354535,"accession_number":"0001193125-22-200017","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revolution Medicines raises $248M net in public offering of 13.225M shares at $20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 13.225M shares (including full exercise of underwriters' option) at $20.00 per share public price.","Net proceeds of approximately $248.0M after underwriting discounts and offering expenses.","Underwriters include J.P. Morgan, Cowen, Guggenheim; lock-up period of 60 days for directors and officers.","Offering closed on July 22, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354534,"accession_number":"0001193125-22-192292","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Revolution Medicines appoints Lorence Kim to Board, replacing Neil Exter","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kim appointed Class I director effective July 12, 2022, filling vacancy from Exter's resignation.","Determined independent; qualifies as audit committee financial expert; served on Audit Committee.","Venture Partner at Third Rock Ventures, former CFO of Moderna, and ex-Managing Director at Goldman Sachs.","Received initial option for 36,800 shares and 10,500 RSUs under Non-Employee Director Compensation Program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372530,"accession_number":"0001193125-22-177651","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Revolution Medicines stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected three Class II directors: Sushil Patel, Eric Schmidt, Thilo Schroeder with substantial support.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2022 (62.1M for, 6,377 against).","Advisory approval of named executive officer compensation (53.4M for, 4.6M against, broker non-votes 4.1M).","Advisory vote favored holding future say-on-pay votes annually (57.8M for one year); company will adopt annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372529,"accession_number":"0001193125-22-171994","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Revolution Medicines increases CEO Mark Goldsmith's change-in-control severance to 2x salary plus bonus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance multiplier raised from 1.5x to 2x for CEO Mark Goldsmith upon qualifying termination near a change in control.","Applies to termination without cause or resignation for good reason from 3 months before to 18 months after a change in control.","Amendment approved by Compensation Committee on June 8, 2022, and executed on June 10, 2022.","Lump sum cash payment equals 2x annual base salary plus target annual bonus.","No other terms of the employment agreement were changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372528,"accession_number":"0001193125-22-144970","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q1 net loss $57.6M; RAS(ON) inhibitors advancing toward clinic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $57.6M vs $37.2M YoY; revenue $7.6M from Sanofi collaboration (down from $10.2M).","Cash and securities $518.8M at Mar 31, 2022, down from $577.1M at Dec 31, 2021.","FY 2022 net loss guidance reaffirmed at $260M-290M, including $35M-40M stock-based comp.","IND submitted for RMC-6236 (RAS MULTI); first patient dosing mid-2022. RMC-6291 IND on track for H1 2022.","RMC-4630 Phase 2 combo with sotorasib enrolling; enrollment completion expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":7578000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391341,"accession_number":"0001193125-22-057861","cik":1628171,"company_name":"Revolution Medicines, Inc.","ticker":"RVMD","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revolution Medicines Q4 net loss $52.7M, FY2021 net loss $187.1M; RAS pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $577.1M at Dec 31, 2021 vs $440.7M at Dec 31, 2020.","Total revenue $9.5M Q4 2021 vs $8.8M Q4 2020; FY2021 $29.4M vs $43.0M FY2020 (incl. $8.5M non-cash adjustment).","Net loss $52.7M Q4 2021 vs $34.2M Q4 2020; FY2021 $187.1M vs $108.2M FY2020.","Full year 2022 GAAP net loss guidance $260M-$290M; stock-based comp $35M-$40M.","RMC-4630+sotorasib Phase 2 first patient dosed; IND plans: RMC-6236 & RMC-6291 H1 2022, RMC-9805 H1 2023, RMC-8839 H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":29390000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32527259179.721096,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-28T23:59:59+00:00|391341"}